Life Technologies Forms Team to Focus on IP Licensing for PCR, other Products | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies officials said this week that the company has formed a licensing team that will focus on offsetting declining royalty revenues for its PCR-related intellectual property and other IP.

During a conference call to discuss the company's third-quarter financial results, Life Tech Chairman and CEO Greg Lucier said that the company has assembled a team of the "best licensing people" from its Applied Biosystems and Invitrogen businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.